Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 291
Filtrer
9.
J Virol ; 97(12): e0133023, 2023 Dec 21.
Article de Anglais | MEDLINE | ID: mdl-37966249

RÉSUMÉ

IMPORTANCE: The essential steps of successful gene delivery by recombinant adeno-associated viruses (rAAVs) include vector internalization, intracellular trafficking, nuclear import, uncoating, double-stranded (ds)DNA conversion, and transgene expression. rAAV2.5T has a chimeric capsid of AAV2 VP1u and AAV5 VP2 and VP3 with the mutation A581T. Our investigation revealed that KIAA0319L, the multiple AAV serotype receptor, is not essential for vector internalization but remains critical for efficient vector transduction to human airway epithelia. Additionally, we identified that a novel gene WDR63, whose cellular function is not well understood, plays an important role in vector transduction of human airway epithelia but not vector internalization and nuclear entry. Our study also discovered the substantial transduction potential of rAAV2.5T in basal stem cells of human airway epithelia, underscoring its utility in gene editing of human airways. Thus, the knowledge derived from this study holds promise for the advancement of gene therapy in the treatment of pulmonary genetic diseases.


Sujet(s)
Bronches , Dependovirus , Épithélium , Techniques de transfert de gènes , Vecteurs génétiques , Transduction génétique , Humains , Protéines de capside/génétique , Protéines de capside/métabolisme , Dependovirus/génétique , Dependovirus/métabolisme , ADN , Épithélium/métabolisme , Épithélium/virologie , Techniques de transfert de gènes/tendances , Thérapie génétique/méthodes , Vecteurs génétiques/génétique , Bronches/métabolisme , Bronches/virologie , Transport nucléaire actif , Édition de gène/tendances
13.
Rev. derecho genoma hum ; (57): 161-181, July-December 2022.
Article de Anglais | IBECS | ID: ibc-219446

RÉSUMÉ

The present work has the objective of analyzing whether the practice of gene editing, from the teleological foundation, can generate a scenario of neoeugenic choices. This study analyzes the current stage of gene editing, together with the panorama of neoeugenic practices, to delimit the distinctive aspects between these concepts, based on the desired purpose in the practice of gene editing. For that, the analytical-discursive method was used, identifying fundamental connections related to the problem and interpreting the concepts presented in search of an adequate response to the objectives raised. The research was based on scientific articles published in specialized journals, as well as books and chapters in collective works. (AU)


El presente trabajo tiene como objetivo analizar si la práctica de la edición genética, desde el fundamento teleológico, puede generar un escenario de elecciones neoeugenésicas. Este estudio analiza la etapa actual de la edición de genes, junto con el panorama de las prácticas neoeugenésicas, con el fin de delimitar los aspectos distintivos entre estos conceptos, en función de la finalidad deseada en la práctica de la edición de genes. Para ello se utilizó el método analítico-discursivo, identificando conexiones fundamentales relacionadas con el problema e interpretando los conceptos presentados en busca de una respuesta adecuada a los objetivos planteados. La investigación se basó en artículos científicos publicados en revistasespecializadas, así como en libros y capítulos de obras colectivas. (AU)


Sujet(s)
Humains , Édition de gène/éthique , Édition de gène/législation et jurisprudence , Édition de gène/tendances , Questions bioéthiques/législation et jurisprudence , Génome humain/génétique , Biotechnologie/législation et jurisprudence
14.
JAMA ; 328(22): 2195-2197, 2022 12 13.
Article de Anglais | MEDLINE | ID: mdl-36416851

RÉSUMÉ

This Medical News article is an interview with conference chair Manesh Patel, MD, chief of cardiology at the Duke University School of Medicine.


Sujet(s)
COVID-19 , Cardiologie , Édition de gène , Triglycéride , Humains , Association américaine du coeur , Édition de gène/tendances
16.
Nat Rev Genet ; 23(1): 5-22, 2022 01.
Article de Anglais | MEDLINE | ID: mdl-34363067

RÉSUMÉ

Gene drives are selfish genetic elements that are transmitted to progeny at super-Mendelian (>50%) frequencies. Recently developed CRISPR-Cas9-based gene-drive systems are highly efficient in laboratory settings, offering the potential to reduce the prevalence of vector-borne diseases, crop pests and non-native invasive species. However, concerns have been raised regarding the potential unintended impacts of gene-drive systems. This Review summarizes the phenomenal progress in this field, focusing on optimal design features for full-drive elements (drives with linked Cas9 and guide RNA components) that either suppress target mosquito populations or modify them to prevent pathogen transmission, allelic drives for updating genetic elements, mitigating strategies including trans-complementing split-drives and genetic neutralizing elements, and the adaptation of drive technology to other organisms. These scientific advances, combined with ethical and social considerations, will facilitate the transparent and responsible advancement of these technologies towards field implementation.


Sujet(s)
Systèmes CRISPR-Cas , Forçage génétique/méthodes , Édition de gène/méthodes , Génétique des populations/méthodes , /génétique , Allèles , Animaux , Forçage génétique/tendances , Édition de gène/tendances , Humains , Modèles génétiques , Mutation , /métabolisme
17.
Int J Mol Sci ; 22(21)2021 Oct 20.
Article de Anglais | MEDLINE | ID: mdl-34768751

RÉSUMÉ

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and its associated proteins (Cas) is an adaptive immune system in archaea and most bacteria. By repurposing these systems for use in eukaryote cells, a substantial revolution has arisen in the genome engineering field. In recent years, CRISPR-Cas technology was rapidly developed and different types of DNA or RNA sequence editors, gene activator or repressor, and epigenome modulators established. The versatility and feasibility of CRISPR-Cas technology has introduced this system as the most suitable tool for discovering and studying the mechanism of specific genes and also for generating appropriate cell and animal models. SOX genes play crucial roles in development processes and stemness. To elucidate the exact roles of SOX factors and their partners in tissue hemostasis and cell regeneration, generating appropriate in vitro and in vivo models is crucial. In line with these premises, CRISPR-Cas technology is a promising tool for studying different family members of SOX transcription factors. In this review, we aim to highlight the importance of CRISPR-Cas and summarize the applications of this novel, promising technology in studying and decoding the function of different members of the SOX gene family.


Sujet(s)
Édition de gène/méthodes , Facteurs de transcription SOX/génétique , Facteurs de transcription SOX/métabolisme , Animaux , Systèmes CRISPR-Cas/génétique , Clustered regularly interspaced short palindromic repeats/génétique , Édition de gène/tendances , Génie génétique/méthodes , Génome , Humains , Tumeurs/génétique , Tumeurs/thérapie , Cellules souches/métabolisme
18.
Int J Mol Sci ; 22(21)2021 Oct 26.
Article de Anglais | MEDLINE | ID: mdl-34768969

RÉSUMÉ

Inherited retinal degenerations (IRDs) are a diverse group of conditions that are often characterized by the loss of photoreceptors and blindness. Recent innovations in molecular biology and genomics have allowed us to identify the causative defects behind these dystrophies and to design therapeutics that target specific mechanisms of retinal disease. Recently, the FDA approved the first in vivo gene therapy for one of these hereditary blinding conditions. Current clinical trials are exploring new therapies that could provide treatment for a growing number of retinal dystrophies. While the field has had early success with gene augmentation strategies for treating retinal disease based on loss-of-function mutations, many novel approaches hold the promise of offering therapies that span the full spectrum of causative mutations and mechanisms. Here, we provide a comprehensive review of the approaches currently in development including a discussion of retinal neuroprotection, gene therapies (gene augmentation, gene editing, RNA modification, optogenetics), and regenerative stem or precursor cell-based therapies. Our review focuses on technologies that are being developed for clinical translation or are in active clinical trials and discusses the advantages and limitations for each approach.


Sujet(s)
Thérapie cellulaire et tissulaire/tendances , Thérapie moléculaire ciblée/tendances , Dégénérescence de la rétine/génétique , Dégénérescence de la rétine/thérapie , Édition de gène/tendances , Thérapie génétique/tendances , Humains , Neuroprotection , Optogénétique/tendances , Médecine régénérative/tendances
19.
CRISPR J ; 4(5): 728-738, 2021 10.
Article de Anglais | MEDLINE | ID: mdl-34661427

RÉSUMÉ

Over the past two decades, the discovery of CRISPR-Cas immune systems and the repurposing of their effector nucleases as biotechnological tools have revolutionized genome editing. The corresponding work has been captured by 90,000 authors representing 7,600 affiliations in 126 countries, who have published more than 19,000 papers spanning medicine, agriculture, and biotechnology. Here, we use tech mining and an integrated bibliometric and networks framework to investigate the CRISPR literature over three time periods. The analysis identified seminal papers, leading authors, influential journals, and rising applications and topics interconnected through collaborative networks. A core set of foundational topics gave rise to diverging avenues of research and applications, reflecting a bona fide disruptive emerging technology. This analysis illustrates how bibliometrics can identify key factors, decipher rising trends, and untangle emerging applications and technologies that dynamically shape a morphing field, and provides insights into the trajectory of genome editing.


Sujet(s)
Bibliométrie , Systèmes CRISPR-Cas , Édition de gène/tendances , Animaux , Humains
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...